Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Vitrolife AB, headquartered in Sweden, is a leading player in the reproductive health industry, specialising in products and services for assisted reproductive technology (ART). Founded in 1994, the company has established a strong presence in key operational regions, including Europe, North America, and Asia.
Vitrolife is renowned for its innovative solutions, including culture media, cryopreservation products, and laboratory equipment designed to enhance the success rates of IVF treatments. Their commitment to quality and research has positioned them as a trusted partner for fertility clinics worldwide. With a focus on advancing reproductive medicine, Vitrolife continues to achieve significant milestones, solidifying its reputation as a pioneer in the field.
+29 vs industry average
Vitrolife’s score of 71 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2025, Vitrolife reported total carbon emissions of approximately 20.7 million kg CO2e, comprising 610,000 kg CO2e from Scope 1, 1,260,000 kg CO2e from Scope 2, and 18,849,000 kg CO2e from Scope 3 emissions. This represents a slight decrease from 2023, where total emissions were about 21.6 million kg CO2e. The company has set ambitious near-term targets, committing to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030 from a 2023 base year. Additionally, Vitrolife aims to cut Scope 3 emissions from various categories, including purchased goods and services, by 51.6% per million SEK value added within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and reflect Vitrolife's commitment to addressing climate change and reducing its carbon footprint. The company is headquartered in Sweden and operates within the healthcare equipment and supplies sector.
2030
42% reduction in Scope 1
Vitrolife Group commits to reduce absolute scope 1 GHG emissions 42% by 2030 from a 2023 base year.
2030
42% reduction in Scope 2
Vitrolife Group commits to reduce absolute scope 2 GHG emissions 42% by 2030 from a 2023 base year.
2030
51.6% reduction in scope 3 total
Vitrolife Group also commits to reduce scope 3 GHG emissions from purchased goods and services, capital goods, fuel- and energy-related acti…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Vitrolife’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more